AVNS / Avanos Medical, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Avanos Medical, Inc. Announces Second Quarter 2025 Results

Investor Contact: Scott Galovan Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Second Quarter 2025 Results ALPHARETTA, Ga., August 5, 2025/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2025 financial results. “Building off our first qu

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, David Pacitti, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mis

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Scott M.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36440 AVANOS MEDI

Offer Letter by and between Avanos Medical, Inc. and Scott Galovan

5405 Windward Parkway Alpharetta, GA 30004 T 1-844-4AVANOS www.avanos.com July 25, 2025 Mr. Scott Galovan via Email Delivery Dear Scott, Congratulations! We are pleased to appoint you to the position of Sr Vice President, Chief Financial Officer at Avanos Medical. In this role you will report to Dave Pacitti, the Chief Executive Officer of Avanos. Your effective date will be August 1, 2025. Compen

Avanos Medical Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical

Avanos Medical Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical ALPHARETTA, Ga.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 AVANOS MEDICAL, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, David Pacitti, Chief Executive Officer of Avanos Medical, Inc.

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Scott M. Galovan, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors ALPHARETTA, Ga.

Powers of Attorney

Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Mojirade James, with full power to act alone, his or her true and lawful attorney-in-fact, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the Registration Sta

As filed with the Securities and Exchange Commission on June 18, 2025.

As filed with the Securities and Exchange Commission on June 18, 2025. File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorporation or organization) (IRS Employer Ident

Calculation of Filing Fee

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) AVANOS MEDICAL, INC.

Avanos Medical, Inc. 2021 Long Term Incentive Plan, as amended

Exhibit 99.1 Avanos Medical, Inc. 2021 Long Term Incentive Plan As amended on April 27, 2023 and April 24, 2025 1.PURPOSE This 2021 Equity Participation Plan, as amended (the “Plan”), of AVANOS MEDICAL, INC. (the “Corporation”) is intended to aid in attracting and retaining highly qualified personnel and to encourage those persons who materially contribute to the success of the Corporation or of a

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01. and 1.02 of Form SD

EXHIBIT 1.01 Avanos Medical, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 I.Introduction This Conflict Minerals Report (this “Report”) by Avanos Medical, Inc. is for the period from January 1, 2024 to December 31, 2024 (the “Reporting Period”). Unless the context otherwise indicates, the terms “Avanos,” “Company,” “we,” “us,” and “our” mean Avanos Medical, Inc. and its consol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (Address of

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Jason M. Pickett, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, David Pacitti, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mis

Avanos Medical, Inc. Announces First Quarter 2025 Results

Investor Contact: Scott Galovan Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces First Quarter 2025 Results ALPHARETTA, Ga., May 6, 2025/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2025 financial results. “In my first couple of weeks at

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, David Pacitti, Chief Executive Officer of Avanos Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36440 AVANOS MED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File N

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Jason M.

Separation and Consulting Agreement dated April 28, 2025 by and between Avanos Medical, Inc. and Michael C. Greiner

EXHIBIT 10.1 SEPARATION AND CONSULTING AGREEMENT This SEPARATION AND CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and between Avanos Medical, Inc. (together with its subsidiaries, the “Company”) and Michael C. Greiner (“Employee”). The Company and Employee are collectively referred to herein as the “Parties.” RECITALS: WHEREAS, Employee is currently empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 AVANOS MEDICAL, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission Fil

Full and Final Release of Claims and Covenant Not to Sue dated April 28, 2025 by and between Avanos Medical, Inc. and Michael C. Greiner

EXHIBIT 10.2 AVANOS MEDICAL, INC. FULL AND FINAL RELEASE OF CLAIMS AND COVENANT NOT TO SUE This Full and Final Release of Claims and Covenant not to Sue (“Agreement”) is made and entered into between Michael C. Greiner (“Employee”) and Avanos Medical, Inc., a Delaware corporation (the “Company”). 1. SEPARATION FROM EMPLOYMENT. Employee’s employment is terminated and Employee’s last day on the payr

Amendment Dated April 28, 2025 to Employment Offer Letter for Jason M. Pickett

EXHIBIT 10.3 5405 Windward Parkway Alpharetta, GA 30004 T 1-844-428-2667 www.avanos.com April 28, 2025 Mr Jason Pickett Delivered via Hand Delivery Re: Amendment to November, 2014 Offer Letter Jason, Based on the discussions with the Board of Directors, this amendment will memorialize the changes to the role and compensation of your original offer letter that have gone into effect. Role Effective

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 AVANOS MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 AVANOS MEDICAL, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission Fil

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission f

Amendment dated April 14, 2025 to Consulting Agreement dated December 2, 2024 by and between Avanos Medical, Inc. and Blueprint Strategy and Management Consulting, LLC

EXHIBIT 10.1 Avanos Medical, Inc. 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 April 14, 2025 Mr. Warren Machan Blueprint Strategy and Management Consulting, LLC 12355 Clairmonte Ave. Alpharetta, GA 30009 Re: Amendment to Consulting Agreement (the “Consulting Agreement”) dated December 2, 2024 by and between Avanos Medical, Inc. (the “Company”) and Blueprint Strategy and Management C

Avanos Medical, Inc. Second Amended and Restated Severance Pay Plan, effective November 30, 2020,

Exhibit 10.2 AVANOS MEDICAL, INC. SEVERANCE PAY PLAN Second Amended and Restated Plan Effective November 30, 2020 1 Exhibit 10.2 TABLE OF CONTENTS ARTICLE TITLE I NAME, PURPOSE AND EFFECTIVE DATE OF PLAN II DEFINITIONS III ELIGIBILITY AND PARTICIPATION IV SEVERANCE BENEFITS VPLAN ADMINISTRATION VILIMITATIONS AND LIABILITIES APPENDIX A - COVERED EMPLOYERS 1 Exhibit 10.2 ARTICLE I NAME, PURPOSE AND

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission Fil

Offer letter dated March 14, 2025, by and between Avanos Medical, Inc. and David Pacitti

March 14, 2025 Mr. David Pacitti Dear Dave, We are pleased to extend to you an offer of employment to join Avanos in the position of Chief Executive Officer. In this role, you will report to the Board of Directors. Start Date Your anticipated start date is April 14, 2025. Base Salary Your starting salary will be $1,050,000 per year and is subject to applicable withholding and deductions. Consisten

Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer ALPHARETTA, Ga., March 17, 2025/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Paci

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ¨ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ¨ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical, Inc. (Exa

Powers of Attorney, filed herewith.

Exhibit No. 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint Mojirade James and John J. Hurley, with full power to act alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Avanos Medical, Inc. Annual Repor

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results ALPHARETTA, Ga., Feb. 26, 2025/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2024 results. “We are

Subsidiaries of the Corporation, filed herewith.

Exhibit No. 21 Avanos Medical, Inc. Subsidiaries Company Jurisdiction of Incorporation or Organization Avanos Medical (Shanghai) Co., Ltd. China Avanos Medical (Thailand) Limited Thailand Avanos Medical Australia Pty Ltd. Australia Avanos Medical Belgium BVBA Belgium Avanos Medical Brasil Consultoria Ltda. Brazil Avanos Medical Brasilia, LLC Delaware Avanos Medical Canada Inc. Canada Avanos Medica

Section 302 CFO Certification, filed herewith.

Exhibit No. 31(b) CERTIFICATIONS I, Warren J. Machan, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Section 906 CFO Certification, furnished herewith.

Exhibit No. 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Warren J. Machan, Interim Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 26, 2025 (“accompanied report”) fully complies with the requirements of Sec

Section 906 CEO Certification, furnished herewith.

Exhibit No. 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C. Greiner, Interim Chief Executive Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 26, 2025 (“accompanied report”) fully complies with the requirements of S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 26, 2025 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission

Section 302 CEO Certification, filed herewith.

Exhibit No. 31(a) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, n

Michael Greiner Interim CEO January 13, 2025 Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business pl

Michael Greiner Interim CEO January 13, 2025 Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon current plans and management’s expectations and beliefs concerning future events impacting the Company.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 13, 2025 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission f

Consulting Agreement dated December 2, 2024 by and between Avanos Medical, Inc. and Blueprint Strategy and Management Consulting, LLC, incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on December 3, 2024

Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT ("Consulting Agreement") is made and entered into on December 2, 2024, by and between Avanos Medical, Inc., a Delaware corporation (together with its affiliates, "Company"), and Blueprint Strategy and Management Consulting, LLC, a Georgia limited liability company ("Consultant"). RECITALS: WHEREAS, Company desires to engage Consultant as

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 2, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission f

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 01, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission

Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO ALPHARETTA, Ga., October 30, 2024/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Warren J.

Avanos Medical, Inc. Amended and Restated Executive Severance Plan, incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on October 30, 2024

AVANOS MEDICAL, INC. EXECUTIVE SEVERANCE PLAN Amended and Restated as of October 29, 2024 1. Preamble and Statement of Purpose. The purpose of this Plan is to assure the Corporation that it will have the continued dedication of, and the availability of objective advice and counsel from, key executives of the Corporation notwithstanding the possibility, threat or occurrence of a change of control o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 28, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission f

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Warren J. Machan, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

First Amendment dated June 26, 2024 to Credit Agreement dated June 24, 2022 by and among Avanos Medical, Inc., the guarantors party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. (“JPM”) as administrative agent, MUFG Bank, Ltd. (“MUFG”), PNC Bank, National Association (“PNC”) and U.S. Bank National Association (“U.S. Bank”) as co-syndication agents, and JPM, MUFG, PNC and U.S. Bank as joint lead arrangers and joint bookrunners, filed herewith

Exhibit 4.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “First Amendment”) dated as of June 26, 2024, is by and among AVANOS MEDICAL, INC., a Delaware corporation (the “Borrower”), THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent for the Lenders (in such capacity “Agent”). WHEREAS, the Borrower, the Guarantors, the Lenders party

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Separation and Consulting Agreement

SEPARATION AND CONSULTING AGREEMENT This SEPARATION AND CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of October 28, 2024 by and between Avanos Medical, Inc.

Amendment date October 28, 2024 to Employment Offer Letter for Michael C. Greiner, incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on October 30, 2024

5405 Windward Parkway Alpharetta, GA 30004 T 1-844-428-2667 www.avanos.com October 28, 2024 Mr Michael Greiner Delivered via Hand Delivery Re: Amendment to December, 2019 Offer Letter Michael, Based on discussions with the Board of Directors, this amendment memorializes the changes to your December 12, 2019 offer letter that have gone into effect. Role Effective as of the close of business on Octo

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Second Amendment to Employment Offer Letter dated June 21, 2024 for Mojirade James, filed herewith

5405 Windward Parkway Alpharetta, GA 30004 T 1-844-4AVANOS www.avanos.com June 21, 2024 Ms Mojirade James Delivered via Hand Delivery Re: Amendment to May 21, 2021 Offer Letter Moji, Based on our discussion over the past few months, I wanted to use this amendment to memorialize the changes to the Relocation and Travel sections of your original offer letter and subsequent amendments that have gone

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Employment Offer Letter dated March 30, 2024 for Sigfrido Delgado, filed herewith

5405 Windward Parkway Alpharetta, GA 30004 T 1-844-4AVANOS www.avanos.com 03/28/2024 Sig Delgado Dear Sig, We are pleased to extend to you an offer of employment to join Avanos Medical in the position of Senior Vice President, Integrated Supply Chain. In this role you will report to Joe Woody, the Chief Executive Officer of Avanos. Start Date Your anticipated start date is 5/6/2024. Compensation A

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MEDI

Avanos Medical, Inc. Announces Second Quarter 2024 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Second Quarter 2024 Results ALPHARETTA, Ga., July 31, 2024/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2024 financial results. “We are pleased with our

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 31, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission file

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors ALPHARETTA, Ga., July 1, 2024 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced that Indrani Franchini has been appointed as a new

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 28, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission file

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01. and 1.02 of Form SD

EXHIBIT 1.01 Avanos Medical, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 I.Introduction This Conflict Minerals Report (this “Report”) by Avanos Medical, Inc., is for the period from January 1, 2023 to December 31, 2023 (the “Reporting Period”). Unless the context otherwise indicates, the terms “Avanos,” “Company,” “we,” “us,” and “our” mean Avanos Medical, Inc. and its conso

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 (State or other jurisdiction of incorporation) (Commission File Number) 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (Address of principal executive officers) (Zip Code) Michae

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain ALPHARETTA, Ga., May 13, 2024 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced that Sigfrido (Sig) Delgado

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 13, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission file

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MED

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Avanos Medical, Inc. Announces First Quarter 2024 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces First Quarter 2024 Results ALPHARETTA, Ga., May 2, 2024/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2024 financial results. “As we begin the second year

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 2, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission file n

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 25, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ¨ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ¨ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 1

Section 302 CFO Certification, filed herewith.

Exhibit No. 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, n

Subsidiaries of the Corporation, filed herewith.

Exhibit No. 21 Avanos Medical, Inc. Subsidiaries Company Jurisdiction of Incorporation or Organization Avanos Medical (Shanghai) Co., Ltd. China Avanos Medical (Thailand) Limited Thailand Avanos Medical Australia Pty Ltd. Australia Avanos Medical Belgium BVBA Belgium Avanos Medical Brasil Consultoria Ltda. Brazil Avanos Medical Brasilia, LLC Delaware Avanos Medical Canada Inc. Canada Avanos Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical

Section 906 CFO Certification, furnished herewith.

Exhibit No. 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C. Greiner, Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 21, 2024 (“accompanied report”) fully complies with the requirements of Section 1

Section 302 CEO Certification, filed herewith.

Exhibit No. 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Section 906 CEO Certification, furnished herewith.

Exhibit No. 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F. Woody, Chief Executive Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 21, 2024 (“accompanied report”) fully complies with the requirements of Section 13(a

Avanos Medical, Inc. Incentive Compensation Clawback Policy, filed herewith.

Exhibit 97.1 Avanos Medical, Inc. Incentive Compensation Clawback Policy 1.0General. 1.1 Avanos Medical, Inc. (the “Company”) has adopted this Policy in accordance with the applicable listing standards of the New York Stock Exchange (“NYSE”) and Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which require listed companies to adopt and comply with a compensat

Avanos Medical, Inc. Amended and Restated Policy on Insider Trading and Tipping,

Exhibit 19.1 Avanos Medical, Inc. Amended and Restated Policy on Insider Trading And Tipping October 27, 2023 The Company’s Code of Conduct prohibits employees from using non-public information about the Company to trade in stocks or securities. This Policy further details that obligation. All employees, officers, and directors are expected to comply with this Policy and any applicable securities

Powers of Attorney, filed herewith.

Exhibit No. 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint Mojirade James and John J. Hurley, with full power to act alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Avanos Medical, Inc. Annual Repor

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2023 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2023 Results ALPHARETTA, Ga., Feb. 20, 2024/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2023 results. “We wer

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 20, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission

AVNS / Avanos Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0370-avanosmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Avanos Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 05350V106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat

AVNS / Avanos Medical, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Avanos Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05350V106 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

AVNS / Avanos Medical, Inc. / Paradice Investment Management LLC Passive Investment

SC 13G/A 1 paradice-avns123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Avanos Medical, Inc. (Name of Issuer) Common Stock - $0.01 Par Value (Title of Class of Securities) 05350V106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri

Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook ALPHARETTA, Ga., January 4, 2024/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 4, 2024 (Date of earliest event reported) AVANOS MEDICAL, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 4, 2024 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission fi

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 1, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incor

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Avanos Medical, Inc. Announces Third Quarter 2023 Results Strong Free Cash Flow Generation in Excess of $25 Million

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Third Quarter 2023 Results Strong Free Cash Flow Generation in Excess of $25 Million ALPHARETTA, Ga., November 1, 2023/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported thir

First Amendment to Purchase Agreement dated as of October 2, 023 by and between Avanos Medical, Inc. and SunMed Group Holdings, LLC, incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed on October 2, 2023

Exhibit 2.2 FIRST AMENDMENT TO PURCHASE AGREEMENT This FIRST AMENDMENT TO PURCHASE AGREEMENT, is dated as of October 2, 2023 (this “Amendment”), by and among Avanos Medical, Inc., a Delaware corporation (“Parent”), and SunMed Group Holdings, LLC, a Delaware limited liability company (“Buyer”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to them

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission Fi

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 9, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpo

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 9, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpo

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Purchase Agreement dated as of June 7, 2023 by and among Avanos Medical, Inc., the other Sellers party thereto and SunMed Group Holdings, LLC, incorporated by reference to Exhibit 2.1 of our Quarterly Report on Form 10-Q filed on August 9, 2023

PURCHASE AGREEMENT Dated as of June 7, 2023 by and among Avanos Medical, Inc., the Sellers party hereto and SunMed Group Holdings, LLC ARTICLE I DEFINITIONS 1 Section 1.01 Certain Defined Terms 1 Section 1.02 Definitions 16 ARTICLE II PURCHASE AND SALE 19 Section 2.01 Purchase and Sale of Purchased Assets 19 Section 2.02 Assumption and Exclusion of Liabilities 23 Section 2.03 Purchase Price; Alloc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MEDI

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Avanos Medical, Inc. Announces Second Quarter 2023 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Second Quarter 2023 Results ALPHARETTA, Ga., August 9, 2023/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2023 financial results. “We posted solid second

Q2 2023 Earnings Presentation August 9th, 2023 Getting patients back to the things that matter. Chief Executive Officer 2 Joe Woody Michael Greiner Senior Vice President, CFO & Chief Transformation Officer Business Progress Against 2023 Priorities Q2

Q2 2023 Earnings Presentation August 9th, 2023 Getting patients back to the things that matter.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2023 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Commission file number 001-36440 Delaware 46-4987888 (State or other jurisdiction of incorpor

Avanos Medical, Inc. 2021 Long Term Incentive Plan, as amended, incorporated by reference to Exhibit 99.1 to our Registration Statement on Form S-8 filed on July 13, 2023

Exhibit 99.1 Avanos Medical, Inc. 2021 Long Term Incentive Plan As amended on April 27, 2023 1.PURPOSE This 2021 Equity Participation Plan (the “Plan”) of AVANOS MEDICAL, INC. (the “Corporation”) is intended to aid in attracting and retaining highly qualified personnel and to encourage those persons who materially contribute to the success of the Corporation or of an Affiliate (by managerial, scie

As filed with the Securities and Exchange Commission on July 13, 2023.

As filed with the Securities and Exchange Commission on July 13, 2023. File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorporation or organization) (IRS Employer Ident

Powers of Attorney

Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Mojirade James, with full power to act alone, his or her true and lawful attorney-in-fact, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the Registration Sta

alculation of Filing Fee

Calculation of Filing Fee Tables Form S-8 (Form Type) AVANOS MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value Other (4

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.2 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Agreement to Acquire Diros Technology Inc. Unique tined-probe technology further differentiates Avanos portfolio ALPHARETTA, Ga., June 19, 2023 /PRNewswire/ - Avanos Medical, Inc. (NYSE:

Investor Day June 20, 2023 Welcome & Opening Remarks Joe Woody Chief Executive Officer Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections,

avnsform8k6202023xex991 Investor Day June 20, 2023 Welcome & Opening Remarks Joe Woody Chief Executive Officer Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon current plans and management’s expectations and beliefs concerning future events impacting the Company.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2023 AVANOS MEDICAL, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2023 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 AVANOS MEDICAL, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Sale of Respiratory Health Business to SunMed Group Holdings, LLC ALPHARETTA, Ga., June 8, 2023 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 (State or other jurisdiction of incorporation) (Commission File Number) 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (Address of principal executive officers) (Zip Code) Michae

Conflict Minerals Report for the year ended December 31, 2022 as required by Items 1.01 and 1.02 of this Form.

EXHIBIT 1.01 Avanos Medical, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 I.Introduction This Conflict Minerals Report (“Report”) by Avanos Medical, Inc., is for the period from January 1, 2022 to December 31, 2022 (“Reporting Period”). Unless the context otherwise indicates, “Avanos,” “Company,” “we,” “us,” and “our” mean Avanos Medical, Inc. and its consolidated and combine

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MED

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Avanos Medical, Inc. Announces First Quarter 2023 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces First Quarter 2023 Results ALPHARETTA, Ga., May 3, 2023/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2023 financial results. “Our first quarter results we

Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 27, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpo

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Avanos Medical, Inc. Amended and Restated Executive Severance Plan, incorporated by reference to Exhibit 10.23 to our Quarterly Report on Form 10-Q filed on May 3, 2023

AVANOS MEDICAL, INC. EXECUTIVE SEVERANCE PLAN Amended and Restated as of February 14, 2023 1. Preamble and Statement of Purpose. The purpose of this Plan is to assure the Corporation that it will have the continued dedication of, and the availability of objective advice and counsel from, key executives of the Corporation notwithstanding the possibility, threat or occurrence of a change of control

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Severance and Separation Agreement dated January 10, 2023 by and between Avanos Medical, Inc. and William D. Haydon, incorporated by reference to Exhibit 10.22 of our Quarterly Report on Form 10-Q filed on May 3, 2023

SEVERANCE AND SEPARATION AGREEMENT This SEVERANCE AND SEPARATION AGREEMENT (this “Agreement”) is made and entered into as of January 10, 2023 by and between Avanos Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ¨ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ¨ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2023 (Date of earliest event reported) Commission file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inco

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Appoints Dr. Lisa Egbuonu-Davis to Board of Directors ALPHARETTA, Ga., March 6, 2023 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced that Dr. Lisa Egbuonu-Davis, MD, currently v

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2023 (Date of earliest event reported) Commission file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical

Subsidiaries of the Corporation, filed herewith.

Exhibit No. 21 Avanos Medical, Inc. Subsidiaries Company Jurisdiction of Incorporation or Organization Avanos Medical (Shanghai) Co., Ltd. China Avanos Medical (Thailand) Limited Thailand Avanos Medical Australia Pty Ltd. Australia Avanos Medical Belgium BVBA Belgium Avanos Medical Brasil Consultoria Ltda. Brazil Avanos Medical Brasilia, LLC Delaware Avanos Medical Canada Inc. Canada Avanos Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) Commission fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inc

Amendment to Employment Offer Letter dated November 10, 2022 for Arjun Sarker, filed herewith

GETTING PΔTIENTS BΔCK TO WHΔT MΔTTERS INNOVΔTE EVERY DΔY July 27, 2022 Mr. Arjun Sarker 101 Thomson Road #17-03 United Square Singapore 307591 Dear Arjun, We are delighted to continue your employment with Avanos, relocating at your request your position of Senior Vice President, International Commercial, to Avanos Singapore Pte. Ltd. ("Avanos Singapore"), a wholly owned subsidiary of Avanos Medica

Employment Offer Letter dated October 6, 2022 for Sudhakar Varshney, incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K filed on February 21, 2023

October 6, 2022 Mr. Sudhakar Varshney Via email Dear Sudhakar: We are pleased to extend to you an offer of employment to join Avanos Medical, Inc. (“Avanos”) in the position of Senior Vice President, Global Supply Chain and Procurement. In this role, you will report directly to Joe Woody, the Chief Executive Officer of Avanos. Start Date Your anticipated start date is November 14, 2022. Compensati

Section 302 CFO Certification, filed herewith.

Exhibit No. 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, n

Section 906 CFO Certification, furnished herewith.

Exhibit No. 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C. Greiner, Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 21, 2023 (“accompanied report”) fully complies with the requirements of Section 1

Section 302 CEO Certification, filed herewith.

Exhibit No. 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Amendment to Employment Offer Letter dated November 15, 2022 for Mojirade James, filed herewith

5405 Windward Parkway Alpharetta, GA 30004 T 1-844-428-2667 www.avanos.com November 15, 2022 Ms Mojirade James Delivered via Hand Delivery Re: Amendment to May 21, 2021 Offer Letter Moji, Based on our discussion over the past year, I wanted to use this amendment to memorialize the changes to the Relocation and Travel sections of your original offer letter that have gone into effect. Relocation The

Powers of Attorney, filed herewith.

Exhibit No. 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint Mojirade James, with full power to act alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Avanos Medical, Inc. Annual Report on Form 10-K for

Section 906 CEO Certification, furnished herewith.

Exhibit No. 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F. Woody, Chief Executive Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 21, 2023 (“accompanied report”) fully complies with the requirements of Section 13(a

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2022 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2022 Results ALPHARETTA, Ga., Feb. 21, 2023/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2022 results. “We wer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 14, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inco

AVNS / Avanos Medical Inc / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avanos Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05350V106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

AVNS / Avanos Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Avanos Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 05350V106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

AVNS / Avanos Medical Inc / Paradice Investment Management LLC Passive Investment

SC 13G/A 1 paradice-avns123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Avanos Medical, Inc. (Name of Issuer) Common Stock - $0.01 Par Value (Title of Class of Securities) 05350V106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri

Avanos Medical, Inc. Announces New Leadership Appointments

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces New Leadership Appointments ALPHARETTA, Ga., Jan. 11, 2023 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced two executive leadership appointments that support the compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) Commission file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incor

1 UPDATE & TRANSFORMATION DISCUSSION JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2023 2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation, including expectations and planning assumptions, any comments abou

a2023avanosvfa01 1 UPDATE & TRANSFORMATION DISCUSSION JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2023 2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon current plans and management’s expectations and beliefs concerning future events impacting the Company.

Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected]

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement ALPHARETTA, Ga., Nov. 14, 2022 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced that Sudhak

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 14, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inco

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 2, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incor

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Change in Accounting Principle Preferability Letter, filed herewith

Exhibit 18 November 2, 2022 The Board of Directors of Avanos Medical, Inc. 5405 Windward Parkway Alpharetta, GA 30004 Dear Sirs/Madams: At your request, we have read the description included in your Quarterly Report on Form 10-Q to the Securities and Exchange Commission for the quarter ended September 30, 2022, of the facts relating to change in accounting principle from valuing U.S. inventory usi

Avanos Medical, Inc. Announces Third Quarter 2022 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Third Quarter 2022 Results ALPHARETTA, Ga., November 2, 2022/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2022 financial results. ?We are very pleased wit

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 7, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorp

Retention Incentive Agreement dated May 20, 2022 by and between Avanos Medical, Inc. and David E. Ball, incorporated by reference to Exhibit 10.18 of our Quarterly Report on Form 10-Q filed on August 9, 2022

RETENTION INCENTIVE AGREEMENT This RETENTION INCENTIVE AGREEMENT (?Agreement?) is made and entered into as of the 20th day of May 2022 by and between Avanos Medical, Inc.

Section 906 CFO Certification, furnished herewith

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 9, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpo

Section 302 CFO Certification, filed herewith

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MEDI

Section 906 CEO Certification, furnished herewith

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Credit Agreement dated June 24, 2022 by and among Avanos Medical, Inc., the guarantors party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. (“JPM”) as administrative agent, MUFG Bank, Ltd. (“MFUG”), PNC Bank, National Association (“PNC”) and U.S. Bank National Association (“U.S. Bank”) as co-syndication agents, and JPM, MUFG, PNC and U.S. Bank as joint lead arrangers and joint bookrunners, incorporated by reference to Exhibit 4.3 of our Quarterly Report on Form 10-Q filed on August 9, 2022

EXECUTION VERSION CREDIT AGREEMENT Dated as of June 24, 2022 among AVANOS MEDICAL, INC.

Avanos Medical, Inc. Amended and Restated Executive Severance Plan

AVANOS MEDICAL, INC. EXECUTIVE SEVERANCE PLAN Amended and Restated as of March 4, 2022 1. Preamble and Statement of Purpose. The purpose of this Plan is to assure the Corporation that it will have the continued dedication of, and the availability of objective advice and counsel from, key executives of the Corporation notwithstanding the possibility, threat or occurrence of a change of control of t

Section 302 CEO Certification, filed herewith

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Avanos Medical, Inc. Announces Second Quarter 2022 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Second Quarter 2022 Results ALPHARETTA, Ga., August 9, 2022/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2022 financial results. ?Despite ongoing raw mat

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 24, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpor

Conflict Minerals Report for the year ended December 31, 2021 as required by Items 1.01 and 1.02 of this Form.

EX-1.01 2 avns2021formsdex101.htm EXHIBIT 1.01 CONFLICT MINERALS REPORT EXHIBIT 1.01 Avanos Medical, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 I.Introduction This Conflict Minerals Report (“Report”) by Avanos Medical, Inc., is for the period from January 1, 2021 to December 31, 2021 (“Reporting Period”). Unless the context otherwise indicates, “Avanos,” “Company,” “we,” “u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 46-4987888 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (Address of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 19, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpora

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 16, 2022 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Commission file number 001-36440 Delaware 46-4987888 (State or other jurisdiction of incorpora

Section 302 CEO Certification

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpo

Avanos Medical, Inc. Announces First Quarter 2022 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces First Quarter 2022 Results ALPHARETTA, Ga., May 4, 2022/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2022 financial results. ?Coming off last year?s solid

Section 906 CFO Certification

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MED

Section 302 CFO Certification

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Section 906 CEO Certification

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

DEF 14A 1 tm223935-3def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) x Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Defini

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2022 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inco

Certification, furnished herewith.

Exhibit No. 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F. Woody, Chief Executive Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 23, 2022 (“accompanied report”) fully complies with the requirements of Section 13(a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical

Certification, filed herewith.

Exhibit No. 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not

Certification, filed herewith.

Exhibit No. 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this annual report on Form 10-K of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, n

Certification, furnished herewith.

Exhibit No. 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C. Greiner, Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge: (1)the Form 10-K, filed with the Securities and Exchange Commission on February 23, 2022 (“accompanied report”) fully complies with the requirements of Section 1

Powers of Attorney, filed herewith.

Exhibit No. 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint Mojirade James, with full power to act alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Avanos Medical, Inc. Annual Report on Form 10-K for

Subsidiaries of the Corporation, filed herewith.

Exhibit No. 21 Avanos Medical, Inc. Subsidiaries Company Jurisdiction of Incorporation or Organization Arabian Medical Products Manufacturing Company Saudi Arabia Avanos Medical (Shanghai) Co., Ltd. China Avanos Medical (Thailand) Limited Thailand Avanos Medical Australia Pty Ltd. Australia Avanos Medical Belgium BVBA Belgium Avanos Medical Brasil Consultoria Ltda. Brazil Avanos Medical Brasilia,

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2021 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. [email protected] Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2021 Results ALPHARETTA, Ga., Feb. 23, 2022/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2021 results. ?We are

AVNS / Avanos Medical Inc / Paradice Investment Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

AVNS / Avanos Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Avanos Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 05350V106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ?

AVNS / Avanos Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Avanos Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05350V106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 20, 2022 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36440 46-4987888 (State or other jurisdiction of incorporation) (Commission F

Merger Agreement, dated December 13, 2021, by and among Avanos Medical, Inc., Avent, Inc., Orthogen Merger Sub, Inc. and OrthogenRx, Inc.

AGREEMENT AND PLAN OF MERGER AMONG AVENT INC., ORTHOGEN MERGER SUB INC., ORTHOGENRX, INC., SHAREHOLDER REPRESENTATIVE SERVICES LLC, solely in its capacity as Representative (as defined herein) AND AVANOS MEDICAL, INC., solely for purposes of Section 13.18 of this Agreement December 13, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 Interpretation 18 ARTICLE II THE MERGER

First Amendment to Amended and Restated Credit Agreement, dated as of December 22, 2021, by and among Avanos Medical, Inc. and Citibank N.A., as administrative agent, incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K filed on January 21, 2022

Execution Version FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this ?First Amendment?) dated as of December 22, 2021, is by and among AVANOS MEDICAL, INC.

Incremental Agreement, dated December 22, 2021, by and among Avanos Medical, Inc., the guarantors party thereto, the lenders party thereto, Citibank N.A., as administrative agent, and J.P. Morgan Chase Bank N.A. and MUFG Bank, LTD, as joint lead arrangers, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed on January 21, 2022

INCREMENTAL AGREEMENT THIS INCREMENTAL AGREEMENT (this ?Incremental Agreement?) dated as of December 22, 2021, is by and among AVANOS MEDICAL, INC.

1 J.P. MORGAN HEALTHCARE CONFERENCE JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2022 2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation and webcast, including expectations and planning assumptions and any

1 J.P. MORGAN HEALTHCARE CONFERENCE JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2022 2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation and webcast, including expectations and planning assumptions and any estimates, projections, and statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute forward-lo

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 11, 2022 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Commission file number 001-36440 Delaware 46-4987888 (State or other jurisdiction of incor

EXHIBIT A

Avanos Medical, Inc. 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 January 6, 2022 VIA EDGAR SUBMISSION Mr. Michael Fay Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street NE Washington, D.C. 205479 Re: Avanos Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 19, 2021 File No. 001-36440 Dear Mr. Fay: Th

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 15, 2021 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Commission file number 001-36440 Delaware 46-4987888 (State or other jurisdiction of inco

Avanos Medical, Inc.

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected] AVANOS MEDICAL, INC. ANNOUNCES SHARE REPURCHASE AUTHORIZATION ALPHARETTA, Ga., Dec. 15, 2021 /PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today announced that its Board of Directors has a

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 13, 2021 (Date of earliest event reported) AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Commission file number 001-36440 Delaware 46-4987888 (State or other jurisdiction of inco

Avanos Medical, Inc.

Exhibit 99.1 Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected] Avanos Medical, Inc. Announces Agreement to Acquire OrthogenRX, Inc. Intra-articular injections products enhance pain portfolio with additional treatment options ALPHARETTA, Ga., Dec. 13, 202

As of December 31, 2021 2020 Domestic $ — $ 110.0 Foreign — 65.3 Total Property, Plant and Equipment $ — $ 175.3

Avanos Medical, Inc. 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 November 23, 2021 VIA EDGAR and EMAIL Mr. Michael Fay Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street NE Washington, D.C. 205479 Re: Avanos Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 19, 2021 File No. 001-36440 Dear Mr. Fay: T

Avanos Medical, Inc. Announces Third Quarter 2021 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected] Avanos Medical, Inc. Announces Third Quarter 2021 Results ALPHARETTA, Ga., November 2, 2021/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2021 financial results. ?We continu

Section 906 CFO Certification

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 302 CFO Certification

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 2, 2021 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incor

Section 906 CEO Certification

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

Section 302 CEO Certification

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 29, 2021 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of inc

Section 302 CEO Certification

Exhibit 31(a) CERTIFICATIONS I, Joseph F. Woody, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the ?registrant?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m

Form of Award Agreements related to the Avanos Medical, Inc. 2021 Long Term Incentive Plan, incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed on August 3, 2021

Exhibit 10.3 AVANOS MEDICAL, INC. NONQUALIFIED STOCK OPTION AWARD AGREEMENT AVANOS MEDICAL, INC., a Delaware corporation (hereinafter called the "Corporation"), has granted to the participant (the ?Participant) named in the Notification of Grant Award provided on the Fidelity Investments (?Fidelity?) site, or any successor system (the ?Grant Notice?) an option to purchase shares of Common Stock of

Section 302 CFO Certification

Exhibit 31(b) CERTIFICATIONS I, Michael C. Greiner, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the “registrant”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, no

Avanos Medical, Inc. Announces Second Quarter 2021 Results

Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected] Avanos Medical, Inc. Announces Second Quarter 2021 Results ALPHARETTA, Ga., August 3, 2021/PRNewswire/ - Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2021 financial results. ?Through th

Employment Offer Letter dated May 21, 2021 for Mojirade James, incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on August 3. 2021

Exhibit 10.2 5405 Windward Parkway Alpharetta, GA 30004 T 1-844-425-9273 avanos.com May 21, 2021 Ms. Mojirade James 1900 Hamilton Street Apt D18 Philadelphia, PA 19130 Dear Mojirade: We are pleased to extend to you an offer of employment to join Avanos Medical, Inc. (?Avanos?) in the position of Senior Vice President & General Counsel. In this role, you will report directly to Joe Woody, the Chief

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 29, 2021 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpor

Section 906 CFO Certification

Exhibit 32(b) Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Michael C.

Section 906 CEO Certification

Exhibit 32(a) Certification of Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code I, Joseph F.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36440 AVANOS MEDI

Powers of Attorney

EX-24.1 4 avns2021forms8ex241.htm EXHIBIT 24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints S. Ross Mansbach, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sig

Avanos Medical, Inc. 2021 Long Term Incentive Plan.

Exhibit 99.1 Avanos Medical, Inc. 2021 Long Term Incentive Plan 1. PURPOSE This 2021 Equity Participation Plan (the ?Plan?) of AVANOS MEDICAL, INC. (the ?Corporation?) is intended to aid in attracting and retaining highly qualified personnel and to encourage those persons who materially contribute to the success of the Corporation or of an Affiliate (by managerial, scientific or other innovative m

As filed with the Securities and Exchange Commission on July 19, 2021.

As filed with the Securities and Exchange Commission on July 19, 2021. File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorporation or organization) (IRS Employer Ident

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 12, 2021 (Date of earliest event reported) Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction of incorpor

Investor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected]

Exhibit 99.1 Investor Contact: Dave Crawford Avanos Medical, Inc. 470-448-5177 [email protected] Media Contact: Katrine Kubis Avanos Medical, Inc. 470-448-5561 [email protected] Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel ALPHARETTA, Ga., July 12, 2021 / PRNewswire / - Avanos Medical, Inc. (NYSE: AVNS) today announced that Moji J